Bli medlem
Bli medlem

Du är här


ExpreS2ion Biotechnologies: Pareto Securities and Analysguiden publish research reports with increased price targets of SEK 68 and SEK 55, respectively

Hørsholm, Denmark, August 25, 2021 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its `buy' rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK 55 per share. Both of these reports were published before the August 23, 2021 announcement that the Danish Ministry of Health will fund the ABNCoV2 COVID-19 vaccine program with up to DKK 800 million. 

Both research reports are available on the Analyst Reports ( page of ExpreS[2]ion's investor website. The next updates from Pareto Securities and Analysguiden are expected following major news.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732


For further information about ExpreS[2]ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

Keith Alexander, CFO

Telephone: +45 5131 8147

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.